Gender-affirming hormone therapy and cardiovascular health in transgender adults
Climacteric. 2024 Apr 10:1-9. doi: 10.1080/13697137.2024.2310518. Online ahead of print.ABSTRACTA growing number of people identify as transgender and gender non-binary in the USA and worldwide. Concomitantly, an increasing number of patients are receiving gender-affirming hormone therapy (GAHT) to achieve gender congruence. GAHT has far-ranging effects on clinical and subclinical markers of cardiovascular risk. Transgender patients also appear to be at higher risk for cardiovascular diseases compared to their cisgender peers and the impact of gender-affirming therapy on cardiovascular health is unclear. Studies on the eff...
Source: Climacteric - April 10, 2024 Category: Geriatrics Authors: Caroline Ong Monique Monita Minghao Liu Source Type: research
Gender-affirming hormone therapy and cardiovascular health in transgender adults
Climacteric. 2024 Apr 10:1-9. doi: 10.1080/13697137.2024.2310518. Online ahead of print.ABSTRACTA growing number of people identify as transgender and gender non-binary in the USA and worldwide. Concomitantly, an increasing number of patients are receiving gender-affirming hormone therapy (GAHT) to achieve gender congruence. GAHT has far-ranging effects on clinical and subclinical markers of cardiovascular risk. Transgender patients also appear to be at higher risk for cardiovascular diseases compared to their cisgender peers and the impact of gender-affirming therapy on cardiovascular health is unclear. Studies on the eff...
Source: Climacteric - April 10, 2024 Category: Geriatrics Authors: Caroline Ong Monique Monita Minghao Liu Source Type: research
Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer
CONCLUSIONS: These results provide a strong rationale to investigate 225Ac-pelgi in patients with prostate cancer. A clinical phase 1 study has been initiated (NCT06052306).PMID:38593212 | DOI:10.1158/1078-0432.CCR-23-3746 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 9, 2024 Category: Cancer & Oncology Authors: Christoph A Schatz Sabine Zitzmann-Kolbe Ingrid Moen Monika Klotz Shankari Nair Stefan Stargard Roger M Bjerke Katrine Wickstr øm Biseth Yuan Zeng Feng B ård Indrevoll V éronique Cruciani Jenny Karlsson Bernard Haendler Carsten H Nielsen Maria Z Alfsen Source Type: research
Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer
CONCLUSIONS: These results provide a strong rationale to investigate 225Ac-pelgi in patients with prostate cancer. A clinical phase 1 study has been initiated (NCT06052306).PMID:38593212 | DOI:10.1158/1078-0432.CCR-23-3746 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Christoph A Schatz Sabine Zitzmann-Kolbe Ingrid Moen Monika Klotz Shankari Nair Stefan Stargard Roger M Bjerke Katrine Wickstr øm Biseth Yuan Zeng Feng B ård Indrevoll V éronique Cruciani Jenny Karlsson Bernard Haendler Carsten H Nielsen Maria Z Alfsen Source Type: research
Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan
CONCLUSIONS: The anticipated association between AI exposure and osteoporotic fracture risk in Japanese women with breast cancer was not seen clearly.PMID:38588537 | DOI:10.1080/14656566.2024.2340712 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 8, 2024 Category: Drugs & Pharmacology Authors: Tetsuya Taguchi Hisashi Matsushima Sho Kodama Naoki Okubo Tetsuo Ito Maja Ludwikowska Seiji Fukumoto Toshio Matsumoto Source Type: research
Menopausal hormone therapy and risk of venous thromboembolism: The story so far
Afr J Reprod Health. 2024 Mar 31;28(3):122-129. doi: 10.29063/ajrh2024/v28i3.13.ABSTRACTMenopausal hormone therapy (MHT) is known to increase the risk of venous thromboembolism (VTE), which includes deep vein thrombosis, pulmonary embolism, and less frequently cerebral vein thrombosis, but the absolute risk for a given patient is very low. After starting MHT, the risk of VTE seems to be at its highest, declining to the non-HRT user baseline level of risk after stopping. Whether estrogen-only or estrogen-progestin HRT combination is linked to a similar risk of VTE is unclear from the available evidence. The aim of this stud...
Source: African Journal of Reproductive Health - April 7, 2024 Category: African Health Authors: Mohsen M A Abdelhafez Karim A M Ahmed Nashwa A M Ahmed Mohd H Ismail Mohd N M Daud Aya M E Eldiasty Mohd F B Amri Mohammad S Jeffree Fairrul K Masnah Dg M P Baharuddin Mohd F Bolong Mohd F Hayati Nornazirah B Azizan Doreen Sumpat Syed S S Abdul Rahim Win Source Type: research
Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants
Afr J Reprod Health. 2024 Mar 31;28(3):99-113. doi: 10.29063/ajrh2024/v28i3.11.ABSTRACTMenopause represents the physiological transition when a woman's reproductive period ends associated with a variety of symptoms, including vasomotor symptoms, such as night sweats and hot flashes. This systematic review and meta-analysis aimed to assess the effectiveness and safety of oral Fezolinetant for treating vasomotor symptoms associated with menopause. Five electronic databases were searched from their inception until May 2023. Via the Cochrane risk of bias tool, two reviewers assessed the studies' quality. The primary outcomes w...
Source: African Journal of Reproductive Health - April 7, 2024 Category: African Health Authors: Amal M Elhusein Hammad A Fadlalmola Huda H Abedelwahed Alaw ìa A Elshaikh Amel E Banaga Manal H F Alrahman Nafesa H Abdelgadim Insaf H Mohammed Afaf A A Abdalla Fatma A M Abdalla Ebtihag M Abd Allah Nagwa I Abbas Abdullah D Alhujaili Egbal A Almkiy Eltay Source Type: research
Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047]
Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4. doi: 10.1016/j.annonc.2024.03.010. Online ahead of print.ABSTRACTBACKGROUND: The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage RT for PSA failure.METHODS: RADICALS-RT was a randomised controlled trial enrolling patients with ≥1 risk factor (pT3/4, Gleason 7-10, positive margins, pre-op PSA≥10ng/ml) for recurrence after radical prostatectomy. Patients were randomised 1:1 to adjuvant RT ("Adjuvant-RT") or an observation pol...
Source: Cancer Control - April 7, 2024 Category: Cancer & Oncology Authors: C C Parker P M Petersen A D Cook N W Clarke C Catton W R Cross H Kynaston W R Parulekar R A Persad F Saad L Bower G C Durkan J Logue C Maniatis D Noor H Payne J Anderson A K Bahl F Bashir D M Bottomley K Brasso L Capaldi P W Cooke C Chung J Donohue B Eddy Source Type: research
Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047]
Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4. doi: 10.1016/j.annonc.2024.03.010. Online ahead of print.ABSTRACTBACKGROUND: The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage RT for PSA failure.METHODS: RADICALS-RT was a randomised controlled trial enrolling patients with ≥1 risk factor (pT3/4, Gleason 7-10, positive margins, pre-op PSA≥10ng/ml) for recurrence after radical prostatectomy. Patients were randomised 1:1 to adjuvant RT ("Adjuvant-RT") or an observation pol...
Source: Ann Oncol - April 7, 2024 Category: Cancer & Oncology Authors: C C Parker P M Petersen A D Cook N W Clarke C Catton W R Cross H Kynaston W R Parulekar R A Persad F Saad L Bower G C Durkan J Logue C Maniatis D Noor H Payne J Anderson A K Bahl F Bashir D M Bottomley K Brasso L Capaldi P W Cooke C Chung J Donohue B Eddy Source Type: research
Menopausal hormone therapy and risk of venous thromboembolism: The story so far
Afr J Reprod Health. 2024 Mar 31;28(3):122-129. doi: 10.29063/ajrh2024/v28i3.13.ABSTRACTMenopausal hormone therapy (MHT) is known to increase the risk of venous thromboembolism (VTE), which includes deep vein thrombosis, pulmonary embolism, and less frequently cerebral vein thrombosis, but the absolute risk for a given patient is very low. After starting MHT, the risk of VTE seems to be at its highest, declining to the non-HRT user baseline level of risk after stopping. Whether estrogen-only or estrogen-progestin HRT combination is linked to a similar risk of VTE is unclear from the available evidence. The aim of this stud...
Source: African Journal of Reproductive Health - April 7, 2024 Category: African Health Authors: Mohsen M A Abdelhafez Karim A M Ahmed Nashwa A M Ahmed Mohd H Ismail Mohd N M Daud Aya M E Eldiasty Mohd F B Amri Mohammad S Jeffree Fairrul K Masnah Dg M P Baharuddin Mohd F Bolong Mohd F Hayati Nornazirah B Azizan Doreen Sumpat Syed S S Abdul Rahim Win Source Type: research
Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants
Afr J Reprod Health. 2024 Mar 31;28(3):99-113. doi: 10.29063/ajrh2024/v28i3.11.ABSTRACTMenopause represents the physiological transition when a woman's reproductive period ends associated with a variety of symptoms, including vasomotor symptoms, such as night sweats and hot flashes. This systematic review and meta-analysis aimed to assess the effectiveness and safety of oral Fezolinetant for treating vasomotor symptoms associated with menopause. Five electronic databases were searched from their inception until May 2023. Via the Cochrane risk of bias tool, two reviewers assessed the studies' quality. The primary outcomes w...
Source: African Journal of Reproductive Health - April 7, 2024 Category: African Health Authors: Amal M Elhusein Hammad A Fadlalmola Huda H Abedelwahed Alaw ìa A Elshaikh Amel E Banaga Manal H F Alrahman Nafesa H Abdelgadim Insaf H Mohammed Afaf A A Abdalla Fatma A M Abdalla Ebtihag M Abd Allah Nagwa I Abbas Abdullah D Alhujaili Egbal A Almkiy Eltay Source Type: research
Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047]
Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4. doi: 10.1016/j.annonc.2024.03.010. Online ahead of print.ABSTRACTBACKGROUND: The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage RT for PSA failure.METHODS: RADICALS-RT was a randomised controlled trial enrolling patients with ≥1 risk factor (pT3/4, Gleason 7-10, positive margins, pre-op PSA≥10ng/ml) for recurrence after radical prostatectomy. Patients were randomised 1:1 to adjuvant RT ("Adjuvant-RT") or an observation pol...
Source: Ann Oncol - April 7, 2024 Category: Cancer & Oncology Authors: C C Parker P M Petersen A D Cook N W Clarke C Catton W R Cross H Kynaston W R Parulekar R A Persad F Saad L Bower G C Durkan J Logue C Maniatis D Noor H Payne J Anderson A K Bahl F Bashir D M Bottomley K Brasso L Capaldi P W Cooke C Chung J Donohue B Eddy Source Type: research
Menopausal hormone therapy and risk of venous thromboembolism: The story so far
Afr J Reprod Health. 2024 Mar 31;28(3):122-129. doi: 10.29063/ajrh2024/v28i3.13.ABSTRACTMenopausal hormone therapy (MHT) is known to increase the risk of venous thromboembolism (VTE), which includes deep vein thrombosis, pulmonary embolism, and less frequently cerebral vein thrombosis, but the absolute risk for a given patient is very low. After starting MHT, the risk of VTE seems to be at its highest, declining to the non-HRT user baseline level of risk after stopping. Whether estrogen-only or estrogen-progestin HRT combination is linked to a similar risk of VTE is unclear from the available evidence. The aim of this stud...
Source: African Journal of Reproductive Health - April 7, 2024 Category: African Health Authors: Mohsen M A Abdelhafez Karim A M Ahmed Nashwa A M Ahmed Mohd H Ismail Mohd N M Daud Aya M E Eldiasty Mohd F B Amri Mohammad S Jeffree Fairrul K Masnah Dg M P Baharuddin Mohd F Bolong Mohd F Hayati Nornazirah B Azizan Doreen Sumpat Syed S S Abdul Rahim Win Source Type: research
Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants
Afr J Reprod Health. 2024 Mar 31;28(3):99-113. doi: 10.29063/ajrh2024/v28i3.11.ABSTRACTMenopause represents the physiological transition when a woman's reproductive period ends associated with a variety of symptoms, including vasomotor symptoms, such as night sweats and hot flashes. This systematic review and meta-analysis aimed to assess the effectiveness and safety of oral Fezolinetant for treating vasomotor symptoms associated with menopause. Five electronic databases were searched from their inception until May 2023. Via the Cochrane risk of bias tool, two reviewers assessed the studies' quality. The primary outcomes w...
Source: African Journal of Reproductive Health - April 7, 2024 Category: African Health Authors: Amal M Elhusein Hammad A Fadlalmola Huda H Abedelwahed Alaw ìa A Elshaikh Amel E Banaga Manal H F Alrahman Nafesa H Abdelgadim Insaf H Mohammed Afaf A A Abdalla Fatma A M Abdalla Ebtihag M Abd Allah Nagwa I Abbas Abdullah D Alhujaili Egbal A Almkiy Eltay Source Type: research
